Journal of Applied Laboratory Medicine最新文献_第10页

Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test Strips. 评价横向流动免疫法Xylazine试纸条的灵敏度、选择性和交叉反应性。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf037

Lena Scott, Katherine Davis, Ju Nyeong Park, Saman Majeed

{"title":"Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test Strips.","authors":"Lena Scott, Katherine Davis, Ju Nyeong Park, Saman Majeed","doi":"10.1093/jalm/jfaf037","DOIUrl":"10.1093/jalm/jfaf037","url":null,"abstract":"Background: The rise of xylazine-adulterated substances poses significant public health risks due to their severe side effects, creating an urgent need for reliable detection methods. Lateral flow immunoassay-based xylazine test strips (XTS) have emerged as a potential harm reduction tool for quick, easy, and field-based drug checking, but their effectiveness remains underexplored. Although commercial XTS from multiple vendors are available, the lack of regulatory standards raises concerns regarding their accuracy.Methods: This study evaluated the performance of commercially available XTS from 7 different vendors to investigate the interproduct comparison of sensitivity, precision, cross-reactivity, and stability over changes in human urine pH and extended storage under ambient and extreme temperature conditions.Results: All test strips maintained their sensitivity, reproducibility, and effectiveness despite urinary pH fluctuation and storage temperatures over 6 weeks. However, concentration-dependent false-positive results were observed when the strips were tested with drugs and adulterants commonly encountered in seized samples. Interfering compounds including lidocaine, levamisole, ketamine, methamphetamine, diphenhydramine, promethazine, and cetirizine displayed varying degrees of cross-reactivity with different XTS.Conclusions: This study underscores the variability in performance among commercially available XTS, highlighting their implications for use in harm reduction and forensic settings. While XTS are capable of detecting xylazine at low concentrations, the potential for false-positive results due to cross-reactivity with other drugs necessitates caution in their interpretation. Hence, XTS may serve as a viable harm reduction tool, provided that their cross-reactivity limitations are thoroughly documented and they are incorporated as part of a broader harm reduction strategy.","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":" ","pages":"887-900"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The 2024 PhD Board-Certified Clinical Chemist Compensation Survey. 2024 年博士学位委员会认证临床化学家薪酬调查。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf017

Jaime H Noguez, Anna E Merrill, Adam J McShane, Yachana Kataria

{"title":"The 2024 PhD Board-Certified Clinical Chemist Compensation Survey.","authors":"Jaime H Noguez, Anna E Merrill, Adam J McShane, Yachana Kataria","doi":"10.1093/jalm/jfaf017","DOIUrl":"10.1093/jalm/jfaf017","url":null,"abstract":"Background: Board-certified clinical chemists with doctor of philosophy (PhD) degrees are essential to laboratory medicine and healthcare, yet comprehensive data on their total compensation is limited. The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) Society for Young Clinical Laboratorians Core Committee conducted its fifth compensation survey in April 2024, providing updated data on salary, benefits, and job satisfaction among board-certified clinical chemists.Methods: The 2024 compensation survey was distributed to all doctoral-level ADLM members based in the United States and Canada (n = 1576). Confidential, self-reported data were collected from respondents on various demographic and professional characteristics, including academic degree, board certification, years of experience, employment sector, total compensation (defined as base salary plus bonus), geographic location, race/ethnicity, and sex. The study included a total of 291 respondents for analysis.Results: Ninety-two percent (n = 267) of the respondents resided in the United States and 90% held a PhD degree. More than half of the respondents were employed in academic, hospital, or healthcare system settings. Among those with board certification, 86% were certified by the American Board of Clinical Chemistry (ABCC). The median total compensation for ABCC board-certified PhD clinical chemists working in the United States (n = 158) was $220 000 to $229 000.Conclusions: The 2024 survey highlights a continued upward trend in compensation for board-certified PhD clinical chemists, reflecting their expertise and contributions to healthcare. This report serves as a critical resource for professionals to advocate for equitable and competitive compensation as well as benefits that support career advancement and development.","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":" ","pages":"1008-1018"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on Can Hemoglobin A1c Be Greater Than 100%? A Case of Homozygous Hemoglobin J-Iran. 糖化血红蛋白可以大于100%吗？纯合血红蛋白j -伊朗1例。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf020

Sharon M Geaghan

引用次数: 0

Evaluation of the Analytical Sensitivity of a Molecular Point-of-Care Assay as Compared to 3 Lateral Flow Assays for Group A Streptococcus. a群链球菌的分子即时检测与3种横向流动检测的分析敏感性评价

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf042

Alamelu Chandrasekaran, Abdullah Kilic, Rinki Kumar, Daniel A Green, Fann Wu, Gregory J Berry

{"title":"Evaluation of the Analytical Sensitivity of a Molecular Point-of-Care Assay as Compared to 3 Lateral Flow Assays for Group A Streptococcus.","authors":"Alamelu Chandrasekaran, Abdullah Kilic, Rinki Kumar, Daniel A Green, Fann Wu, Gregory J Berry","doi":"10.1093/jalm/jfaf042","DOIUrl":"10.1093/jalm/jfaf042","url":null,"abstract":"Background: An accurate and timely diagnosis of pharyngitis caused by group A streptococcus (GAS) is essential for ensuring appropriate antibiotic therapy. Early detection through point-of-care (POC) testing is valuable in initiating effective treatment. This study aimed at evaluating the analytical sensitivity of the molecular ID NOW™ Strep A 2 POC test as compared to 3 POC lateral flow assays: BD Veritor™ Plus System, Sofia® Strep A+ Fluorescent Immunoassay, and Sekisui Diagnostic OSOM® Strep A test for GAS detection.Methods: Two Streptococcus pyogenes bacterial American Type Culture Collection (ATCC) isolates and one clinical isolate from a throat swab sample were used to evaluate the limit of detection (LoD) of each assay. Ten-fold serial dilutions of the isolates starting from 107 colony factor units (CFU)/mL were prepared, and each dilution was tested in triplicate for all 4 assays simultaneously. All tests were performed as per manufacturers' instructions. The LoD was defined as the last dilution that yielded positive results for all 3 replicates. CFU per swab was also calculated.Results: For the 3 isolates evaluated, LoDs of ID NOW Strep A 2 ranged from 3.125 × 103 to 2.5 × 104 CFU/mL; for Quidel Sofia the range was 1 × 106 to 1 × 107 CFU/mL; for BD Veritor the range was 1 × 107 to 1.5 × 107 CFU/mL; and for Sekisui OSOM the LoD was 1 × 107 CFU/mL for all 3 isolates.Conclusions: Compared to antigen-based lateral flow assays (LFAs), the molecular ID Now Strep A 2 assay demonstrated a lower LoD, which translates into higher sensitivity. In a clinical setting, this could enable detection of samples with a lower bacterial load that could be missed by low-sensitivity LFAs.","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":" ","pages":"901-910"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Point-of-Care Testing Glucometer in Rapid Assessment Settings: Comparison of 2 Network-Capable Devices in a Referral Hospital. 快速评估设置中的即时检测血糖仪：转诊医院2种网络设备的比较

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf048

Giacomo Moretti, Giorgia Degni, Camilla Lamiano, Eugenia Tulli, Andrea Urbani

{"title":"Point-of-Care Testing Glucometer in Rapid Assessment Settings: Comparison of 2 Network-Capable Devices in a Referral Hospital.","authors":"Giacomo Moretti, Giorgia Degni, Camilla Lamiano, Eugenia Tulli, Andrea Urbani","doi":"10.1093/jalm/jfaf048","DOIUrl":"10.1093/jalm/jfaf048","url":null,"abstract":"Background: Point-of-care testing (POCT) glucose meters are essential for rapid glucose monitoring. This study aimed to evaluate the analytical performance of 2 novel network-capable POCT glucometers, CobasPulse (Roche Diagnostic) and StatStrip (Nova Biomedical), in comparison to the Atellica CH 930 Analyzer (Siemens Healthcare), a central laboratory clinical chemistry analyzer, as a reference method.Methods: A cohort of 150 patients' venous whole blood samples were analyzed. Method comparison was performed using Passing-Bablok regression and Bland-Altman plots. Precision studies were conducted using commercial controls, with assessment of within-run and between-run imprecision by experienced laboratory technicians. Performance was assessed against FDA 2020 benchmarks.Results: Passing-Bablok regression showed accurate overlap for both POCT devices. CobasPulse exhibited a bias of -0.17 mmol/L and Pearson r of 0.982, while StatStrip showed a bias of -0.35 mmol/L and Pearson r of 0.959. Within-run CV for Cobas Pulse (3.3 mmol/L control) was 2.4%, and for StatStrip (3.44 mmol/L control) was 5.2%. Between-run CVs were 2.1% for Cobas Pulse and 3.2% for StatStrip at comparable glucose concentrations.Conclusions: Both CobasPulse and StatStrip demonstrated acceptable concordance with the Atellica CH 930 Analyzer. While Cobas Pulse showed slightly better agreement and precision, both devices are suitable for glucose measurements in healthcare settings, providing reliable results and reduced turnaround time, supporting timely clinical decisions for rapid glycemic assessment.","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":" ","pages":"963-968"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Child with a Known Cancer Predisposition Syndrome and an Unusually Aggressive Clinical Course. 一个已知的癌症易感性综合征的儿童和一个异常侵袭性的临床过程。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf001

Maya Ball-Burack, Francisco A Perez, Natalie Waligorski, Shannon M Stasi, Bonnie L Cole, Rebecca Ronsley, Christina Lockwood, Sarah E Leary, Vera Paulson, Michelle A Ting

引用次数: 0

M Protein Interference in Renal Function Assays: A Quest for True Kidney Function. 肾功能检测中的M蛋白干扰：对真实肾功能的探索。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf028

Michelle P van der Helm, Brigitte A Wevers, Cees van Beek, Paul W Schenk, Angela Bikker-Koornneef

引用次数: 0

Healthcare Excellence is a Global Phenomenon. 医疗保健卓越是一种全球现象。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf065

Melissa Ryan, Colleen Strain, Tricia Ravalico

引用次数: 0

Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States. 美国不同孕妇队列中sFlt-1/PlGF比值的测定

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf063

Antonio F Saad, David M Haas, Eugene Chang, Scott A Shainker, Miriah Denbo, Michelle Silasi, George Saade, Sarosh Rana, Tetsuya Kawakita, Luis D Pacheco, Jennifer Powers Carson, Angela Dietl, Deirdre Allegranza, Ge Guo, David Stamilio

{"title":"Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States.","authors":"Antonio F Saad, David M Haas, Eugene Chang, Scott A Shainker, Miriah Denbo, Michelle Silasi, George Saade, Sarosh Rana, Tetsuya Kawakita, Luis D Pacheco, Jennifer Powers Carson, Angela Dietl, Deirdre Allegranza, Ge Guo, David Stamilio","doi":"10.1093/jalm/jfaf063","DOIUrl":"10.1093/jalm/jfaf063","url":null,"abstract":"Background: The serum soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) ratio is an established tool for predicting preeclampsia in many countries but is not widely adopted in the United States. This study aimed to determine reference ranges for the Elecsys® sFlt-1/PlGF ratio and the sFlt-1 and PlGF immunoassays (Roche Diagnostics International Ltd) in a diverse US population of healthy pregnant women.Methods: This was a prospective, noninterventional sample and data collection study performed between November 2022 and November 2023 at 9 collection sites and one measurement site in the United States. Evaluable women were ≥18 years old, apparently healthy, between 23 + 0 to 40 + 6 gestational weeks with a singleton pregnancy and had one serum sample collected. Reference ranges for 23 + 0 to 40 + 6 gestational weeks and 5 gestational windows within this range were determined using a nonparametric method.Results: Of 818 recruited women, 561 were evaluable for the analysis and were representative of the US population in terms of self-reported race, ethnicity, and maternal age. Reference ranges for the sFlt-1/PlGF ratio, as determined by the 2.5th and 97.5th percentiles (90% CIs), were 0.9 (0.7, 1.0) to 13.5 (11.6, 14.9) for a US intended use population at 23 + 0 to 34 + 6 gestational weeks (n = 380) and 0.9 (0.7, 1.1) to 40.8 (29.0, 47.2) for the entire evaluable population at 23 + 0 to 40 + 6 gestational weeks.Conclusions: Reference ranges were determined for sFlt-1/PlGF and the sFlt-1 and PlGF immunoassays in a diverse, healthy US population of pregnant women at 23 + 0 to 40 + 6 gestational weeks.","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":" ","pages":"937-948"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on A Child with a Known Cancer Predisposition Syndrome and an Unusually Aggressive Clinical Course. 一个已知的癌症易感综合征的儿童和一个不寻常的侵略性的临床过程的评论。

IF 1.8

Journal of Applied Laboratory Medicine Pub Date : 2025-07-01 DOI: 10.1093/jalm/jfaf025

Sharon Markham Geaghan

引用次数: 0